Summary Summary Short summary of a recent publication, written by scientific experts. Published: Dec 02, 2018

Could the long noncoding RNA, MALAT‐1, be a therapeutic target in myasthenia gravis?

Takeaway

  • Metastasis‐associated lung adenocarcinoma transcript 1 (MALAT‐1) was reduced in the blood of myasthenia gravis (MG) patients and found to form a regulatory network with miR‐338‐3p and male-specific lethal 2 (MSL2) highlighting its potential as a therapeutic target for MG.

Why this matters

  • The molecular basis of MG is poorly understood and the potential role of MALAT-1 in MG has not been elucidated.